相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells
T. Nii-Kono et al.
KIDNEY INTERNATIONAL (2007)
Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients
Marlies Noordzij et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2006)
The importance of residual renal function in dialysis patients
A. Y-M Wang et al.
KIDNEY INTERNATIONAL (2006)
A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD
AK Pieper et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2006)
Coronary artery calcification, systemic inflammation markers and mineral metabolism in a peritoneal dialysis population
Adriano Luiz Ammirati et al.
NEPHRON CLINICAL PRACTICE (2006)
The kidney disease outcomes quality initiative (K/DOQI) guideline for bone metabolism and disease in CKD: Association with mortality in dialysis patients
M Noordzij et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2005)
Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis
GA Block et al.
KIDNEY INTERNATIONAL (2005)
Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols
IB Salusky et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: The USRDS waves 1, 3, and 4 study
Y Slinin et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis
P Raggi et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients
E Ferramosca et al.
AMERICAN HEART JOURNAL (2005)
Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study
EW Young et al.
KIDNEY INTERNATIONAL (2005)
Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis - A randomized clinical trial
JP Garg et al.
ARTHRITIS AND RHEUMATISM (2005)
Hyperphosphatemia in Chinese peritoneal dialysis patients with and without residual kidney function: What are the implications?
AYM Wang et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2004)
The importance of bone health in end-stage renal disease: out of the frying pan, into the fire?
HH Malluche et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2004)
Peritoneal dialysis-associated peritonitis in Scotland (1999-2002)
D Kavanagh et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2004)
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis
GA Block et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2004)
Arterial calcifications and bone histomorphometry in end-stage renal disease
GM London et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2004)
Dynamic analysis of peritoneal dialysis associated peritonitis
JR Hotchkiss et al.
ASAIO JOURNAL (2004)
Sevelamer hydrochloride: an effective phosphate binder in dialyzed children
H Mahdavi et al.
PEDIATRIC NEPHROLOGY (2003)
Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients
GM Chertow et al.
KIDNEY INTERNATIONAL (2002)
Peritoneal and hemodialysis: I. Differences in patient characteristics at initiation
JL Xue et al.
KIDNEY INTERNATIONAL (2002)
Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease
J Blacher et al.
HYPERTENSION (2001)
分享论文
